Curcumin-piperine supplementation in children with none- alcoholic fatty liver disease

The effect of curcumin-piperine supplementation on inflammatory and oxidative stress factors, sonographic findings and symptom of depression, anxiety and stress in children with nonalcoholic fatty liver disease

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20121216011763N54

Enrollment

Registered

2022-03-28

Start date

2022-03-12

Completion date

Unknown

Last updated

2022-04-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None- alcoholic fatty liver disease. Fatty (change of) liver, not elsewhere classified

Interventions

Intervention 1: Intervention group: Take one capsule containing curcumin piperine daily (containing 500 mg curcumin extract and 5 mg piperine, Sami labs Ltd., India ) for 10 weeks. Intervention 2: Con

Eligibility

Sex/Gender

All

Age

10 Years to 18 Years

Inclusion criteria

Inclusion criteria: Children with non alcoholic fatty liver disease Age 10-18 years old

Exclusion criteria

Exclusion criteria: Presence of hepatitis, Chronic liver disease , Cardiovascular, Renal, Pulmonary, Hypothyroidism diseases and cancer Not consuming drugs that could affect on Alanine aminotransferase level including HMG-COA reductase inhibitors, metformin

Design outcomes

Primary

Measure	Time frame
C-reactive protein. Timepoint: At the beginning of study - week 10. Method of measurement: Biochemical assessment.;Total antioxidant capacity. Timepoint: At the beginning of study - week 10. Method of measurement: Biochemical assessment.;Total oxidant status. Timepoint: At the beginning of study - week 10. Method of measurement: Biochemical assessment.;Oxidative stress index. Timepoint: At the beginning of study - week 10. Method of measurement: Biochemical assessment.	—

Measure

Time frame

C-reactive protein. Timepoint: At the beginning of study - week 10. Method of measurement: Biochemical assessment.;Total antioxidant capacity. Timepoint: At the beginning of study - week 10. Method of measurement: Biochemical assessment.;Total oxidant status. Timepoint: At the beginning of study - week 10. Method of measurement: Biochemical assessment.;Oxidative stress index. Timepoint: At the beginning of study - week 10. Method of measurement: Biochemical assessment.

—

Secondary

Measure	Time frame
Sonographic findings. Timepoint: At the beginning of study - week 10. Method of measurement: Liver ultrasonography.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactGholamreza Askari

Esfahan University of Medical Sciences

askari@mui.ac.ir+98 31 3792 3171

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026